Contraceptive patch.  The patch should not be applied to the palm.
Find information on thousands of medical conditions and prescription drugs.

Ortho Evra

A contraceptive patch is a transdermal patch applied to the skin that releases synthetic estrogen and progestin hormones to prevent pregnancy. They are thought to have the same effectiveness as the contraceptive pill. Currently the only publicly available contraceptive patch is marketed under the brand name Ortho Evra. Use of this relatively new contraceptive is increasing rapidly, likely because it combines the high effectiveness of contraceptive pills with a more convenient and easy method of administration. Contraceptive patches are often referred to by the slang term "the patch". more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

Method of use

In the United States and Canada, Ortho Evra is available only by prescription and is sold in boxes of three patches. Johnson & Johnson is the largest manufacturer of these patches.

A woman applies her first patch onto her upper outer arm, buttocks, abdomen or thigh on either the first day of her menstrual cycle (day 1) or on the first Sunday following that day, whichever she prefers. The day of application is known from that point as patch change day. Seven days later, when patch change day comes again, the woman removes the patch and applies another in its place. This process is repeated again on the next patch change day. On the following patch change day, the patch is removed and not replaced. The woman waits 7 days without a patch in place, and on the next patch change day she applies a new patch.

Backup contraception

  • If a woman chooses to begin with her patch change day as day 1 of her menstrual cycle, the patch is able to take effect in time to prevent ovulation (see Mechanism of Action below) and no form of backup contraception is needed at all.
    • In the case that a woman wishes to begin using the contraceptive patch following a first trimester abortion or miscarriage, patch application can be done immediately afterwards. This can be considered the same as a day 1 start above, and no backup contraception is required.
  • If a woman chooses to begin with her patch change day as the first Sunday following day 1, it is necessary to use a backup form of contraception such as spermicide or condoms for the first week of patch wear.

Mechanism of action

Contraceptive patches are synthetic hormone contraceptives, similar in action to the contraceptive pill. The contraceptive patch product Ortho Evra contains 0.75 mg ethinyl estradiol and 6.0 mg norelgestromin hormones in a single patch. The gradual release of hormones over the course of each week (approximately 20 µg/day ethinyl estradiol and 150 µg/day norelgestromin) act much like contraceptive pills do. Most commonly ovulation is inhibited entirely, preventing pregnancy. Less often the cervical mucus is thickened, making it more difficult for sperm to cross through the cervix and for fertilization to occur.

Interactions and Contraindications

Contraceptive effectiveness of the patch or any other hormonal contraceptive may be reduced significantly if co-administered alongside various antibiotics, antifungals, anticonvulsants, or other drugs that increase metabolism of contraceptive steroids.

However, despite the interactions with many other antibiotics, a clinical pharamacokinetic drug interaction study showed that oral administration of tetracycline HCl 500 mg for 3 days prior to and 7 days during use of Ortho Evra did not reduce effectiveness of Ortho Evra. This is a significant factor in the common decision to administer tetracycline-derived antibiotics following an abortion (preventatively to fight potential infection) when synthetic hormone contraceptives are to be used afterwards.

Read more at Wikipedia.org


[List your site here Free!]


FDA Approves Weekly Birth Control Patch - Ortho Evra approved
From American Family Physician, 1/15/02 by Joanne E. Chatfield

The U.S. Food and Drug Administration (FDA) has approved the first contraceptive patch for use on a weekly basis.

The three-layer, combination, transdermal patch, Ortho Evra, contains 6.00 mg of norelgestromin and 0.75 mg of ethinyl estradiol, releasing 150 mcg and 20 mcg, respectively, into the blood stream every 24 hours. The patch is applied on the same day each week for three consecutive weeks to the buttocks, abdomen, upper torso (front or back, but not breasts), or upper outer arm. The fourth week is patch-free. Results of clinical studies demonstrate a low rate of premature detachment of the patches, and the patches were found to be durable while bathing, swimming, or exercising.

Pregnancy rates from three large, worldwide trials involving 3,300 women who completed 22,155 cycles of the patch were approximately one per 100-women years of use. Of the 15 pregnancies reported, five occurred in women who weighed 198 lb (90 kg) or more (less than 3 percent of the study population), indicating the patch may be less effective in this group of women. The most common adverse events reported included breast symptoms, headache, patch-site irritation, and nausea. It is strongly recommended that women who use the patch quit smoking. As with other combination hormonal contraceptives, the patch is not recommended for use by women who have blood clots, certain cancers, a history of heart attack or stroke, or those who may be pregnant. The patch does not provide protection against sexually transmitted diseases or human immunodeficiency virus, and is not indicated for use as an emergency contraceptive.

Ortho Evra is scheduled to be released to consumers by prescription during the first half of 2002. Additional information is available at http://www.orthoevra.com.

COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group

Return to Ortho Evra
Home Contact Resources Exchange Links ebay